Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Bell Potter Healthcare Conference 2020

10 slides from Kazia Therapeutics's conference presentation, Nov 26, 2020

  1. Slide 1: Kazia Presents to the Bell Potter Healthcare Conference (ASX Release)

    ASX RELEASE 26 November 2020 KAZIA PRESENTS TO THE BELL POTTER HEALTHCARE CONFERENCE Sydney, 26 November 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation to be made by our CEO, Dr James

  2. Slide 2: A company developing innovative, high-impact drugs for cancer

    A company developing innovative, high-impact drugs for cancer Presentation to Bell Potter Healthcare Conference Dr James Garner Chief Executive Officer & Managing Director 26 November 2020 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual

  4. Slide 4: Investment Rationale

    Investment Rationale • Paxalisib developed by Genentech, the world’s most successful cancer drug company • Well-proven mechanism of action, with unique differentiating factor of brain penetration World-Class Asset • Strong scientific rationale for development in brain cancer in Brain Cancer • Encour

  5. Slide 5: Latest phase II data compares well to historical data for temozolomide

    Latest phase II data compares well to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Paxalisib 8.4 months Paxalisib 17.5 months Median PFS Median OS Existing 5.3 months Existing 12.7 months Therapy Median PFS Therapy M

  6. Slide 6: GBM AGILE is the planned pivotal study for paxalisib in glioblastoma

    GBM AGILE is the planned pivotal study for paxalisib in glioblastoma What is GBM AGILE? Who is Behind It? • A ‘platform study’, designed by the leading experts in brain cancer to GBM AGILE is sponsored by the Global expedite the approval of new drugs for glioblastoma Coalition for Adaptive Research

  7. Slide 7: A broad-based clinical program is underway across multiple forms of brain cancer

    A broad-based clinical program is underway across multiple forms of brain cancer Paxalisib (GDC-0084) Primary Brain Cancer Secondary Brain Cancer (brain cancer that begins in the brain) (brain cancer that spreads from elsewhere in the body) Glioblastoma Glioblastoma DIPG Primary CNS Brain Breast Bra

  8. Slide 8: Positive newsflow has supported revaluation of Kazia

    Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation Share Price (AU$) KZA 1.20 Market Capitalisation ~AU$ 100 million 1.00 Shares on Issue ~126 million ASX: KZA Listing NASDAQ: KZIA (1:10 ratio) 0.80 Willoughby Capital 16% Platinum Asset Mgmt. 9% 0.60 Ke

  9. Slide 9: Key Milestones and Anticipated Newsflow

    Key Milestones and Anticipated Newsflow Execution of definitive agreement with GCAR for GBM AGILE pivotal study October 2020 ✓ Further interim data from Kazia phase II glioblastoma trial November 2020 ✓ Initial interim data from phase I DIPG trial at St Jude November 2020 ✓ Initial interim data from

  10. Slide 10: www.kaziatherapeutics.com

    www.kaziatherapeutics.com

Kazia Therapeutics — Bell Potter Healthcare Conference 2020 on 6ix